Hearing focuses on price of Norplant; Wyeth pledges discount for public sector.
D000288:Administrative Personnel; D000569:Americas; D003267:Contraception; D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D003365:Costs and Cost Analysis; D019049:Developed Countries; D004467:Economics; D005193:Family Planning Services; D005376:Financial Management; D005380:Financing, Government; D006076:Government; D006077:Government Agencies; D007221:Industry; D007348:Insurance, Health; D016912:Levonorgestrel; D008389:Marketing of Health Services; D008484:Medicaid; D009656:North America; D009934:Organization and Administration; D009938:Organizations; D011203:Poverty; D011632:Public Assistance; D017150:Public Sector; D012923:Social Class; D012959:Socioeconomic Factors; D014481:United States
D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D016912:Levonorgestrel
Administrative Personnel; Americas; Contraception; Contraception Research; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Implants; Contraceptive Methods; Developed Countries; Economic Factors; Family Planning; Financial Activities; Financing, Government; Government Agencies; Government Officials; Health Insurance; Industry; Levonorgestrel; Low Income Population--women; Macroeconomic Factors; Marketing; Medical Assistance, Title 19; North America; Northern America; Organization And Administration; Organizations; Pricing; Public Assistance; Public Sector; Social Class; Socioeconomic Factors; Socioeconomic Status; United States; Usaid